JP2023531315A5 - - Google Patents
Info
- Publication number
- JP2023531315A5 JP2023531315A5 JP2022581380A JP2022581380A JP2023531315A5 JP 2023531315 A5 JP2023531315 A5 JP 2023531315A5 JP 2022581380 A JP2022581380 A JP 2022581380A JP 2022581380 A JP2022581380 A JP 2022581380A JP 2023531315 A5 JP2023531315 A5 JP 2023531315A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence shown
- formulation according
- formulation
- approximately
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20184004.8 | 2020-07-03 | ||
| EP20184004 | 2020-07-03 | ||
| PCT/AU2021/050714 WO2022000046A1 (en) | 2020-07-03 | 2021-07-05 | High concentration formulation of factor xii antigen binding proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023531315A JP2023531315A (ja) | 2023-07-21 |
| JP2023531315A5 true JP2023531315A5 (enExample) | 2024-07-12 |
| JP7880827B2 JP7880827B2 (ja) | 2026-06-26 |
Family
ID=71514949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022581380A Active JP7880827B2 (ja) | 2020-07-03 | 2021-07-05 | 第ｘｉｉ因子抗原結合タンパク質の高濃度製剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240277839A1 (enExample) |
| EP (1) | EP4175669A4 (enExample) |
| JP (1) | JP7880827B2 (enExample) |
| KR (1) | KR20230035355A (enExample) |
| CN (1) | CN116322764A (enExample) |
| AU (1) | AU2021302684A1 (enExample) |
| BR (1) | BR112022026482A2 (enExample) |
| CA (1) | CA3183508A1 (enExample) |
| CL (1) | CL2023000004A1 (enExample) |
| IL (1) | IL298989A (enExample) |
| MX (1) | MX2022016365A (enExample) |
| WO (1) | WO2022000046A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4337257A1 (en) * | 2021-05-12 | 2024-03-20 | AnaptysBio, Inc. | Antibody composition |
| US20250042984A1 (en) * | 2021-12-20 | 2025-02-06 | CSL Innovation Pty Ltd | Protein formulations and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20250164T1 (hr) | 2011-07-22 | 2025-04-11 | Csl Behring Gmbh | Inhibitorna monoklonska antitijela protiv faktora xii/xiia i njihove uporabe |
| JP5859148B2 (ja) * | 2012-03-08 | 2016-02-10 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ａβ抗体製剤 |
| US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| US8613919B1 (en) * | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
| EP3325516B1 (en) * | 2015-07-21 | 2021-12-15 | Takeda Pharmaceutical Company Limited | A monoclonal antibody inhibitor of factor xiia |
| EP3433274A1 (en) * | 2016-03-25 | 2019-01-30 | Visterra, Inc. | Formulation of antibody molecules to dengue virus |
| EP3440107A4 (en) * | 2016-04-06 | 2020-02-19 | CSL Limited | METHOD FOR TREATING ATHEROSCLEROSIS |
| JOP20170170B1 (ar) * | 2016-08-31 | 2022-09-15 | Omeros Corp | صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق |
| BR112019011900A2 (pt) | 2016-12-23 | 2019-11-26 | Serum Institute Of India Private Limited | métodos melhorados para aumentar a produtividade de anticorpos na cultura de células de mamíferos e minimizar a agregação durante os processos downs-tream, processos de formulação, e formulações de anticorpos estáveis obtidas dos mesmos |
| US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| EA202190056A1 (ru) * | 2018-06-19 | 2021-05-28 | Ридженерон Фармасьютикалз, Инк. | АНТИТЕЛА ПРОТИВ ФАКТОРА XII/XIIa И ИХ ПРИМЕНЕНИЕ |
| US12134657B2 (en) | 2018-11-28 | 2024-11-05 | Oregon Health & Science University | Therapeutic factor XII antibody |
| US20230390418A1 (en) * | 2020-10-29 | 2023-12-07 | Regenxbio Inc. | Vectorized factor xii antibodies and administration thereof |
-
2021
- 2021-07-05 IL IL298989A patent/IL298989A/en unknown
- 2021-07-05 EP EP21834598.1A patent/EP4175669A4/en active Pending
- 2021-07-05 BR BR112022026482A patent/BR112022026482A2/pt unknown
- 2021-07-05 MX MX2022016365A patent/MX2022016365A/es unknown
- 2021-07-05 US US18/004,004 patent/US20240277839A1/en active Pending
- 2021-07-05 KR KR1020237003982A patent/KR20230035355A/ko active Pending
- 2021-07-05 JP JP2022581380A patent/JP7880827B2/ja active Active
- 2021-07-05 CN CN202180053399.8A patent/CN116322764A/zh active Pending
- 2021-07-05 WO PCT/AU2021/050714 patent/WO2022000046A1/en not_active Ceased
- 2021-07-05 AU AU2021302684A patent/AU2021302684A1/en active Pending
- 2021-07-05 CA CA3183508A patent/CA3183508A1/en active Pending
-
2023
- 2023-01-03 CL CL2023000004A patent/CL2023000004A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2505325C (en) | Stabilized single domain antibodies | |
| JP7417421B2 (ja) | 改善された血清アルブミン結合性免疫グロブリン単一可変ドメイン | |
| JP6952019B2 (ja) | 免疫グロブリン単一可変ドメインの安定製剤及びその使用 | |
| AU2003286003B2 (en) | Stabilized single domain antibodies | |
| US20130136736A1 (en) | Single Domain VHH Antibodies Against Von Willebrand Factor | |
| MX2008015852A (es) | Formulaciones liofilizadas de anticuerpos anti-egfr. | |
| KR20140066124A (ko) | 점도가 감소된 제제 | |
| AU2007215012A1 (en) | Antibody formulation | |
| KR20140018966A (ko) | 점도가 감소된 제제 | |
| CN105431453A (zh) | 稳定的双重可变结构域免疫球蛋白制剂 | |
| BR112013004850B1 (pt) | uso de um antagonista do tgf-b na preparação de um medicamento para tratamento de infarto do miocárdio | |
| CN105339010A (zh) | 使用因子xii抑制剂和c1-抑制剂的联合疗法 | |
| JP2019537617A5 (enExample) | ||
| JP2022528230A (ja) | Ｉｌ－５に対する抗体を含有する医薬組成物及びその使用 | |
| JP2020521465A (ja) | 生物医薬組成物および関連の方法 | |
| JP2023515423A (ja) | 抗ｉｌ－４ｒ抗体医薬組成物及びその使用 | |
| IL298989A (en) | High concentration promotion of factor XII antigen binding proteins | |
| NL2013007B1 (en) | Methods of treating TTP with immunoglobulin single variable domains and uses thereof. | |
| JP7403224B2 (ja) | 改良されたｐ２ｘ７受容体結合剤およびこれを含むポリペプチド | |
| JP2024001135A (ja) | Ｔｔｐの初回エピソードを免疫グロブリン単一可変ドメインで処置する方法 | |
| JP7804590B2 (ja) | 抗ｉｌ－３３抗体の処方物 | |
| EP4257603A1 (en) | Pharmaceutical composition comprising anti-connective tissue growth factor antibody | |
| JP7574079B2 (ja) | 小児患者における癌の治療のためのラムシルマブ | |
| JP2025510774A (ja) | 修飾ｆｃドメインを有するｓｉｒｐ－ａｌｐｈａ融合ポリペプチド | |
| CN120437287A (zh) | 一种包含特异性结合gucy2c和cd3的双特异性抗体的药物组合物 |